These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Treatment of chronic heart failure in patients with mitral and aortic valve defects of rheumatic origin].
    Author: Bagirova GG, Batalina MV.
    Journal: Ter Arkh; 2000; 72(9):63-6. PubMed ID: 11076422.
    Abstract:
    AIM: To evaluate efficiency of using ACE inhibitor (capoten) and beta-blocker (atenolol) in diverse mitral and aortic valve defects (MVD and AVD, respectively) of rheumatic etiology complicated by chronic cardiac failure (CCF) of the first and second stages. MATERIAL AND METHODS: The trial enrolled 41 patients with MVD and 21 patients with AVD of rheumatic etiology. 60 of them had CCF. In cross-over study 38 patients with MVD and 21 with AVD received capoten (6.25 mg/day) for 7 days while 33 patients with MVD were treated with atenolol. Exercise tolerance (ET) and hemodynamics (echo-CG) were examined before and after the treatment. RESULTS: Hemodynamic parameters and ET improved after capoten and atenolol treatment in patients with MVD or AVD and in complex disease (stenosis and insufficiency) with predominant insufficiency. No significant hemodynamic changes were induced by the above drugs in patients with isolated mitral and aortic stenoses. CONCLUSION: Capoten vs atenolol has more potent positive effect in CCF patients with MVD or AVD.
    [Abstract] [Full Text] [Related] [New Search]